

May 14, 2026

<b>BSE Limited</b> <b>Listing Department-</b> <b>Phiroze Jeejeebhoy Tower,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001,</b> <b>Scrip Code- 533543,</b>	<b>National Stock Exchange of India Ltd</b> <b>Exchange Plaza, C-1, Block G,</b> <b>Bandra Kurla Complex,</b> <b>Bandra (E)</b> <b>Mumbai – 400 051,</b> <b>Symbol: BROOKS</b>
--	---

Dear Madam/ Sir,

**Sub: Update on Scheme of Arrangement involving Brooks Steriscience Limited ("BSL"), a Joint Venture / Associate of the Company.**

This is further to the earlier intimation on February 6, 2026, relating to the in-principle approval received from The National Stock Exchange of India Limited and BSE Limited ("Stock Exchanges") by Onesource Specialty Pharma Limited for the proposed composite scheme of arrangement and amalgamation (merger by absorption) amongst Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited and Onesource Specialty Pharma Limited, approved by the Board of Directors of BSL ("Proposed Scheme").

In this regard, the Company has been informed by Brooks Steriscience Limited ("BSL") that at the meeting of its Board of Directors held today deliberated the proposed transaction and in the best interest of all stakeholders decided to not pursue the transaction in the current form.

You are requested to kindly take the same in record.

Thanking You.

For **Brooks Laboratories Limited,**

**Krutika Rane**  
**Company Secretary and Compliance Office**  
**Membership No.: 66310**